Advanced Therapies
The armamentarium of medications for the treatment of IBD has expanded significantly in recent years. This overview summarizes advanced therapies currently approved in Switzerland.
Currently approved advanced therapies
In the field of advanced IBD therapies, significant progress has been made in recent years. The long-established class of anti-TNF agents has been complemented by additional therapeutic options, including anti-interleukins, anti-integrins, S1P modulators, and JAK inhibitors.
IBDnet has compiled an overview of the agents currently approved for use (status of information: March 2026).
